Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FNCH NASDAQ:LGVN NASDAQ:RLMD OTCMKTS:ULUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$12.75$13.27$1.27▼$15.85$20.48M1.212,135 shs2,542 shsLGVNLongeveron$1.48+0.7%$1.33$1.14▼$4.88$22.10M0.21745,187 shs74,519 shsRLMDRelmada Therapeutics$0.62-2.7%$0.62$0.24▼$4.37$20.81M0.59967,794 shs193,437 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%-1.92%-7.27%-1.92%+706.96%LGVNLongeveron+3.52%-11.45%+13.08%+4.26%-62.78%RLMDRelmada Therapeutics+0.72%+3.59%-9.74%+116.44%-83.54%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFNCHFinch Therapeutics Group0.7713 of 5 stars0.05.00.00.00.01.70.6LGVNLongeveron3.1512 of 5 stars3.64.00.00.02.71.70.6RLMDRelmada Therapeutics4.7406 of 5 stars3.15.00.04.41.94.21.3ULURULURUN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFNCHFinch Therapeutics Group 0.00N/AN/AN/ALGVNLongeveron 3.25Buy$8.67485.59% UpsideRLMDRelmada Therapeutics 2.25Hold$5.00713.01% UpsideULURULURU 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ALGVNLongeveron$2.39M9.25N/AN/A$1.47 per share1.01RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/AULURULURUN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/ALGVNLongeveron-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)ULURULURUN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ULUR, LGVN, FNCH, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LGVNLongeveron-$0.35N/AN/AN/A$0.41 millionN/A8/6/2025Q2 2025RLMDRelmada Therapeutics-$0.25N/AN/AN/AN/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/AULURULURUN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFNCHFinch Therapeutics GroupN/A3.873.87LGVNLongeveronN/A5.615.61RLMDRelmada TherapeuticsN/A5.295.29ULURULURUN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFNCHFinch Therapeutics Group21.77%LGVNLongeveron10.01%RLMDRelmada Therapeutics45.24%ULURULURUN/AInsider OwnershipCompanyInsider OwnershipFNCHFinch Therapeutics Group44.90%LGVNLongeveron11.20%RLMDRelmada Therapeutics20.70%ULURULURU1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataLGVNLongeveron2014.93 million13.26 millionNot OptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableULURULURU230.57 million30.24 millionNot OptionableULUR, LGVN, FNCH, and RLMD HeadlinesRecent News About These CompaniesNational Indigenous Training Academy recognised for its training excellence at Territory awardsJuly 11, 2025 | ntnews.com.auNVirgin Australia cuts low season direct flights between Brisbane and Red CentreJuly 10, 2025 | thechronicle.com.auTGPs Honor Indigenous Leadership During NAIDOC WeekJuly 7, 2025 | miragenews.comM‘Unacceptable’: Mutitjulu community waiting 10 years for new housingJuly 3, 2025 | skynews.com.auSIndigenous leaders say Uluru town at centre of Voice Referendum is still waiting for housing after 10 years, as bureaucracy stymies growthJuly 3, 2025 | skynews.com.auSFull 50th NAIDOC schedule for Uluru and Ayers Rock Resort released by Voyages Indigenous TourismJune 30, 2025 | townsvillebulletin.com.auTNT Gov backs brand new five day, four night 54km eco walk at Uluru with $10m loanJune 29, 2025 | ntnews.com.auN10 best Australian road trips to do with a caravanJune 28, 2025 | msn.comUgly fight between ‘radical rock climbers’ and traditional owners over world-famous siteJune 27, 2025 | news.com.auNCLP-Backed Eco Walk Enhances Central Australia ExperienceJune 26, 2025 | miragenews.comMVirgin Australia sale offers deals on flights in and out of the TerritoryJune 23, 2025 | ntnews.com.auNLocal 10’s Eco Hero winner’s adventures continue in the Australian OutbackJune 23, 2025 | local10.comLShadows falling across the landJune 21, 2025 | thewest.com.auTUluru with friendsJune 21, 2025 | thewest.com.auTWinter getaways in Queensland: from Brisbane to Cairns and the Great Barrier Reef plus UluruJune 20, 2025 | theaustralian.com.auJess Mauboy always wanted to be a mum. She didn't expect the way it changed her.June 20, 2025 | msn.comUluru Statement from the Heart: All Aboriginal people need access to education, employment and a safe living environmentsJune 17, 2025 | dailytelegraph.com.auDUluru Australia (Mala Walk) Walking TourJune 16, 2025 | msn.comTake That! How to sell Australia’s Northern TerritoryJune 12, 2025 | ttgmedia.comT10 BEST Places to Visit in Australia in 2024 🇦🇺 | Full Travel Guide by Lloyd & MandyJune 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeULUR, LGVN, FNCH, and RLMD Company DescriptionsFinch Therapeutics Group NASDAQ:FNCH$12.75 0.00 (0.00%) As of 07/14/2025 03:53 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Longeveron NASDAQ:LGVN$1.48 +0.01 (+0.68%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Relmada Therapeutics NASDAQ:RLMD$0.62 -0.02 (-2.69%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.ULURU OTCMKTS:ULURULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
